Business
Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board
About this update from Jasper Therapeutics, Inc.
[{"type":"text","content":"Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board and as Senior Clinical Advisor REDWOOD CITY, Calif., June 13, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Edwin J. Tucker as Jasper’s Chief Medical Officer. Concurrently, Jasper also announced the appointment of Dr. Daniel Adelman, who had been serving as Jasper’s Acting Chief Medical Officer, to its Scientific Advisory Board and to the position of Senior Clinical Advisor. “With our clinical program for briquilimab expanding beyond stem cell transplant conditioning into chronic treatment indications such as CSU and LR-MDS, we are thrilled to welcome Edwin to the Jasper leadership team,” said Ron Martell, CEO of Jasper. “Edwin brings an extraordinary depth of clinical and industry experience and a proven track record of leading programs to successful new drug approvals. We look forward to his leadership and contributions as we advance briquilimab toward our next clinical milestones. We are also pleased that we will continue to benefit from Dan Adelman’s guidance in his role on our Scientific Advisory Board as well as our Senior Clinical Advisor for mast cell disease and CSU programs.” “I am excited to be joining the Jasper team during such an important period in the Company’s development,” said Dr. Tucker. “The data derived to date point to the therapeutic potential of briquilimab in chronic mast cell diseases such as urticaria and myelodysplastic syndromes, as well as to its potential as a conditioning agent. Ron and his team have also built a strong organization well-positioned to realize the potential of this asset, and I look forward to contributing my expertise as we advance briquilimab to its next phase of development.” “I am pleased to join everyone at Jasper in welcoming Edwin as Chief Medical Officer, and look forward to working with him to develop briquilimab,” said Dr. Adelman. “Given briquilimab’s u...